United States Diabetes Care Drugs And Devices Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The US diabetes care market represents one of the largest segments within the country's pharmaceutical and medical device industries, serving an estimated 38 million Americans diagnosed with diabetes alongside millions more considered prediabetic. The market spans both drug therapies and delivery devices, with the 2025 valuation of approximately $60.21 billion reflecting robust demand across treatment categories. A 4.58% annual growth rate underscores the persistent and widening burden of diabetes and related metabolic conditions in the United States.

• •Encompasses prescription drugs and delivery devices for Type 1, Type 2, and gestational diabetes management
• •Driven by an estimated 10.5% national diabetes prevalence affecting over 38 million diagnosed Americans
• •Supported by strong insurance coverage including Medicare, Medicaid, and private payer reimbursement frameworks

Rising obesity rates, sedentary lifestyles, and an aging demographic continue to expand the addressable patient population across the United States healthcare system. Advances in drug development, particularly GLP-1 receptor agonists approved for diabetes but widely adopted for weight management, have significantly increased market value and broadened patient access. Simultaneously, growing adoption of continuous glucose monitoring systems offering real-time glucose tracking and improved treatment outcomes has driven substantial expansion within the device segment.

• •National diabetes prevalence has risen steadily alongside obesity rates, now affecting over one in ten Americans
• •GLP-1 drug class demand surged as medications gained dual indication for obesity and cardiovascular risk reduction
• •Medicare and private insurers increasingly reimburse CGMs and advanced insulin delivery technologies

The market is broadly divided into drug therapies and devices, with insulin products representing the largest pharmaceutical subcategory while continuous glucose monitors lead device growth. North America, and the United States in particular, accounts for the dominant share of the regional market due to high per-capita healthcare spending, advanced reimbursement infrastructure, and elevated disease burden compared to other global regions. The non-insulin therapeutics segment, including GLP-1 agonists and SGLT2 inhibitors, has emerged as the fastest-growing category as clinicians favor combination approaches to complex diabetes management.

• •Insulin, GLP-1 receptor agonists, and SGLT2 inhibitors are the three dominant drug categories by revenue
• •Continuous glucose monitors and insulin pumps represent the leading device subsegments experiencing strongest adoption
• •The US commands the majority of the North American diabetes care market share

What are the recent trends and outlook?

Industry trends point toward tighter integration of drug and device technologies, with hybrid closed-loop insulin delivery systems, often called artificial pancreas systems, gaining regulatory clearance and commercial adoption. The market is also seeing increased activity around over-the-counter glucose monitoring options and biosimilar insulin entrants seeking to reduce pricing pressure on established brand-name products. Looking ahead, the convergence of digital health platforms with traditional diabetes management tools, combined with continued GLP-1 adoption for broader metabolic indications, positions the market for sustained growth.

• •Hybrid closed-loop systems integrating real-time CGM data with automated insulin pumps are expanding rapidly
• •Biosimilar insulins and over-the-counter CGM products are introducing new competitive dynamics and consumer choice
• •GLP-1 class medications are broadening into cardiometabolic indications beyond diabetes, enlarging the total addressable market